CIBC World Boosts Inamed Rating

Analyst John Calcagnini points to double-digit sales growth in all the company's divisions

Inamed (IMDC ) posted $0.54 Q2 cash EPS. The company noted that auditors are reviewing its accounting back to 1996. It also increased its 2002 sales estimate. CIBC World upgraded its investment rating on the shares to strong buy from hold.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.